大剂量甲氨蝶呤未能有效预防弥漫大B细胞淋巴瘤中枢神经系统复发
该多中心回顾性研究纳入加拿大阿尔伯塔省2012–2019年诊治的906例18–70岁弥漫大B细胞淋巴瘤患者,评估预防性静脉大剂量甲氨蝶呤(HD-MTX)对中枢神经系统(CNS)复发的预防效果。
要点
- 高危DLBCL患者中,预防性HD-MTX未降低CNS复发风险(11.2% vs. 12.2%)。
- HD-MTX与无进展生存及总生存均无显著关联。
- 需进一步研究确定DLBCL预防CNS复发的最佳策略。
核心结论
- 本研究未证明预防性大剂量甲氨蝶呤在高危DLBCL患者中具有获益。
研究设计与样本
- 多中心回顾性研究,纳入加拿大阿尔伯塔省2012–2019年诊治的906例18–70岁DLBCL患者,中位随访35.3个月(范围0.29–105.7)。
主要发现
- 326例高危患者中115例(35.3%)接受HD-MTX,其中96例(83.5%)CNS-IPI 4–6分,45例(39.1%)双打击淋巴瘤,4例(3.5%)睾丸淋巴瘤。
- HD-MTX中位剂量数为2(范围1–3)。
- 多因素及倾向性评分分析中,HD-MTX与CNS复发、无进展生存或总生存均无关联。
关键数值与推荐
- 省级指南推荐对基于CNS-IPI评分、双打击淋巴瘤或睾丸受累的高危CNS复发患者使用HD-MTX。
临床怎么用
- 在高危DLBCL患者中,不应常规依赖预防性HD-MTX来降低CNS复发风险。
局限性
- 回顾性研究设计可能存在选择偏倚;HD-MTX组样本量有限(115例);中位随访35.3个月可能不足以捕捉全部CNS复发事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Central nervous system (CNS) relapse affects 5% of diffuse large B-cell lymphoma (DLBCL) patients and portends a poor prognosis. Prophylactic intravenous high-dose methotrexate (HD-MTX) is frequently employed to reduce this risk, but there is limited evidence supporting this practice. We conducted a multicenter retrospective study to determine the CNS relapse risk with HD-MTX in DLBCL patients aged 18-70 years treated in Alberta, Canada between 2012 and 2019. Provincial guidelines recommended HD-MTX for patients at high-risk of CNS relapse based upon CNS-IPI score, double-hit lymphoma, or testicular involvement. Among 906 patients with median follow-up 35.3 months (range 0.29-105.7), CNS relapse occurred in 1.9% with CNS-IPI 0-1, 4.9% with CNS-IPI 2-3, and 12.2% with CNS-IPI 4-6 (p < .001). HD-MTX was administered to 115/326 (35.3%) high-risk patients, of whom 96 (83.5%) had CNS-IPI score 4-6, 45 (39.1%) had double-hit lymphoma, and four (3.5%) had testicular lymphoma. The median number of HD-MTX doses was two (range 1-3). Central nervous system relapse risk was similar with versus without HD-MTX (11.2% vs. 12.2%, p = .82) and comparable to previous reports of high-risk patients who did not receive CNS prophylaxis (10-12%). In multivariate and propensity score analyses, HD-MTX demonstrated no association with CNS relapse, progression-free survival, or overall survival. This study did not demonstrate a benefit of prophylactic HD-MTX in this high-risk patient population. Further study is required to determine the optimal strategy to prevent CNS relapse in DLBCL.
引用
- Puckrin R, El Darsa H, Ghosh S, et al. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. Am J Hematol. 2021. PMID: 33811794. doi:10.1002/ajh.26181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。